Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Up 294.2% in January

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 225,242 shares, a growth of 294.2% from the January 15th total of 57,139 shares. Currently, 1.7% of the company’s shares are sold short. Based on an average trading volume of 5,452,621 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 5,452,621 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.7% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Genenta Science Price Performance

GNTA stock traded down $0.01 during midday trading on Friday, hitting $0.88. 17,846 shares of the company’s stock were exchanged, compared to its average volume of 2,078,701. The firm has a 50 day moving average price of $1.33 and a 200-day moving average price of $2.45. Genenta Science has a 12-month low of $0.71 and a 12-month high of $10.00.

Genenta Science (NASDAQ:GNTA) last issued its earnings results on Friday, October 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. Analysts predict that Genenta Science will post -0.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genenta Science

A number of institutional investors have recently modified their holdings of GNTA. Citadel Advisors LLC bought a new position in Genenta Science in the third quarter worth about $41,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Genenta Science during the 4th quarter worth approximately $26,000. Alyeska Investment Group L.P. bought a new stake in shares of Genenta Science in the 4th quarter worth approximately $328,000. Norges Bank acquired a new position in Genenta Science during the 4th quarter valued at approximately $337,000. Finally, Eurizon Capital SGR S.p.A. bought a new position in Genenta Science during the 4th quarter worth $536,000. Institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.